Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Zavesca(R) (miglustat) First Treatment Available In UK And Ireland For Rare Progressive Niemann-Pick Type C Disease
Actelion Ltd (SIX: ATLN) announced the launch of Zavesca® (miglustat) in the UK and Republic of Ireland; the first and only licensed treatment available for people with Niemann-Pick type C (NP-C) disease [1]. NP-C is a rare, genetic disease with significant neurological deterioration that can be fatal and affects infants, children and adults [2,3].

Vitamin D May Halt Lung Function Decline In Asthma And COPD
Vitamin D may slow the progressive decline in the ability to breathe that can occur in people with asthma as a result of human airway smooth muscle (HASM) proliferation, according to researchers at the University of Pennsylvania.
News of the day
Yale Researchers Identify Gene's Role In Promoting Atherosclerosis
Yale University researchers have found that a single gene plays a key role in the development of atherosclerosis in mice. The research provides insight into the causes of atherosclerosis, or the hardening of the arteries caused by a buildup of plaque.
Public Health

Ingelheim And The World Stroke Organization Announce Partnership In The World Stroke Academy

Boehringer Ingelheim announced today that it will become the founding sponsor of the World Stroke Academy, a novel training initiative for stroke professionals being developed by the World Stroke Organization (WSO). This latest educational initiative from the WSO will bring together an international group of stroke experts - led by Professor Michael Brainin of the Danube University Krems, Austria - to provide information about stroke and knowledge for health professionals and medical doctors in order to improve prevention, therapy and management of stroke. Professor Bo Norrving, President of the WSO said: "The World Stroke Academy is a project of the World Stroke Organization and aims at improving education on a global scale. It is a platform open to all stroke societies aiming at global effectiveness of fighting stroke and its physical and mental consequences." Dr. Manfred Haehl, Corporate Senior Vice President Medicine, Boehringer Ingelheim said: "Boehringer Ingelheim is committed to patient care and we are proud to support initiatives that have potential to benefit all patients. Stroke is one of the biggest causes of death and severe disability worldwide, and a great many patients simply don"t have access to specialist care. We hope the World Stroke Academy will contribute to training a new generation of specialists who can help provide that care." The World Health Organization estimates that 5.7 million people in the world die each year from stroke. Among survivors, 40% experience moderate to severe disability and 10% require institutional care. The World Stroke Academy aims to provide a mixture of online and conventional activities to educate and help facilitate training of stroke professionals across all regions of the world. Key objectives of the initiative include: - Promoting knowledge and education on stroke management on a global level according to the WSO mission statement - Improving and standardising educational standards in primary and secondary stroke prevention, acute management and rehabilitation - Leveraging guidelines to ensure best practice is implemented within all regions of the world - Further developing the WSO as a leading global educator. Boehringer Ingelheim


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009